Navigation Links
Scott & White Healthcare study aimed at T-cell lymphoma
Date:7/15/2010

Scott & White's Cancer Research Institute (CRI) is conducting a clinical trial that targets malignant T-cell lymphoma, a type of blood cancer.

Lymphoma, which affects the white blood cells that normally protect against illness, is categorized either as B-cell or T-cell. About 85% of lymphomas are of B-cell origin, and 15% of T-cell origin. T-cell lymphomas are primarily chronic, but they do not respond well to chemotherapy.

Therefore, says Arthur E. Frankel, M.D., director of the Cancer Research Institute and director of Scott & White's Division of hematology/oncology, the need exists to find new agents that can selectively target and kill the malignant T-cells. The research agent under study at Scott & White contains diphtheria targeting malignant T-cells.

"This new targeted protein agent is designed to eliminate tumor cells resistant to chemotherapy," said Dr. Frankel. "The short course of treatment may improve quality of life if successful."

To date, 10 people have enrolled in the clinical trial. Scott & White's CRI will enroll up to 40 subjects to participate in this clinical trial to determine the safest doses for treatment of T-cell lymphoma. Eligible subjects for the study must have failed previous treatment options.

T-cell malignant diseases include MF/Sezary Syndrome, T-cell LGL, PTCL, T-cell CLL, T-cell NHL, angioimmunoblastic T-cell lymphoma, T-cell anaplastic large cell lymphoma, nasal extranodal T-cell lymphoma, enteropathy-type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and hepatosplenic T-cell lymphoma.


'/>"/>

Contact: Katherine Voss
kvoss@swmail.sw.org
254-724-4097
Scott & White Healthcare
Source:Eurekalert

Page: 1

Related medicine news :

1. Scott & White Memorial Hospital uses device to revolutionize treatment of traumatic aortic injury
2. Scott & White Healthcare pathologist is co-investigator on breast cancer study
3. James Scott Farrin Supports Radiothon for Duke Children's Hospital
4. SUNZ Insurance Company Selects Scott Robertson as President
5. Allergy Relief, Chiropractic and Biofeedback Provided at New Absolute Health Clinic in Scottsdale, Arizona
6. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
7. New Varicose Vein Treatment Center Opens in Prescott, Arizona
8. Scottsdale Veterinary Pharmacy Celebrates Success in Business By Dodging Veterinary Drug Shortages
9. Scott & White Healthcare clinical trials target lymphoma, leukemia
10. Scott & White Healthcare physician to help develop global guidelines for Alzheimers
11. Scott Harter at Atrion International Receives EHS Gold Award From PPG Industries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing ... February 2016. Each webinar features a dynamic expert and thoughtful presentation to give ... patients and facilities. Both events are free to attend, but registration is ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... (VRI) within Healthcare, recently partnered with Heart City Health Center to ... nearly 23 years, Heart City Health Center has provided the Elkhart community with ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix announced on Wednesday that ... an emergency medicine professional association, to support the organization's newly established physician group ... of Emergency Medicine, or AAEM, seeks to empower emergency physicians to control their ...
(Date:2/10/2016)... ... 10, 2016 , ... Compliancy Group LLC is pleased to ... throughout the country. The Guard was specifically designed to handle each element required ... regulatory updates, and compliance coaching. , In addition to meeting the compliance needs ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... charity program created to assist the local community. Pledging to select a new ... nonprofit organizations in the area. Their goal is to bring community awareness to ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016 Immune Pharmaceuticals ... company, announced today that it has filed a patent ... and other cancers. --> ... cancer by administration of Ceplene (histamine dihydrochloride) in combination ... methods of predicting the efficacy of Ceplene and IL-2 ...
(Date:2/10/2016)... BEVERLY HILLS, Calif. , Feb. 10, 2016 /PRNewswire/ ... the "Company") today announced a 1-for-100 reverse split of ... at the opening of trading on Thursday, February 11, ... split-adjusted basis under new CUSIP number 76303T308 and temporary ... stock will commence trading under the ticker symbol (RCHA).  ...
(Date:2/10/2016)... -- Astellas Pharma Inc. (TSE: 4503, President and CEO: ... successfully completed, through its indirect wholly-owned subsidiary Laurel Acquisition ... and outstanding shares of common stock of Ocata Therapeutics, ... , "Ocata") for a price of US$8.50 per share ... commenced the Tender Offer on November 19, 2015, U.S. ...
Breaking Medicine Technology: